

## Risk Factors for Bladder Cancer: Results of a Survey of Hospital Patients

Rangrez Shadab<sup>1</sup>, R. B. Nerli<sup>1</sup>, Saziya R. Bidi<sup>1</sup>, Shridhar C. Ghagane<sup>2</sup>

<sup>1</sup>Department of Urology, JN Medical College, and Urinary Biomarkers Research Centre, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India, <sup>2</sup>Department of Biotechnology, Kaher's Dr. Prabhakar Kore Basic Science Research Center, V. K. Institute of Dental Sciences Campus, Nehru Nagar, Belagavi, India

Received: 28 July 2022/Accepted: 30 September 2022



### OPEN ACCESS

#### Correspondence:

R. B. Nerli, Department of Urology, JN Medical College, KLE Academy of Higher Education and Research, JNMC Campus, Belagavi, Karnataka, India. E-mail: rbnerli@gmail.com

**Citation:** Shadab R, Nerli RB, Bidi SR, Ghagane SC. Risk Factors for Bladder Cancer: Results of a Survey of Hospital Patients. J Cancer Allied Spec [Internet]. 2022;8(2):1-7. <https://doi.org/10.37029/jcas.v9i1.485>

**Copyright:** © 2023 Shadab, et al. This is an open access article distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interest:** Nil.

### Abstract

**Introduction:** Several risk factors have been identified in the occurrence of bladder cancer. These include genetic and hereditary factors, smoking and tobacco use, increased body mass index, occupational exposure to certain chemicals and dyes, medical conditions such as chronic cystitis and infectious diseases such as schistosomiasis. This study aimed to evaluate risk factors in patients with bladder cancer. **Materials and Methods:** All patients presenting to the uro-oncology department of the hospital with imaging and histology confirmed bladder cancer were included in the study. Age- and gender-matched patients presenting to the department of urology with benign disorders were prospectively included as controls. All the study subjects and the controls completed a self-administered structured questionnaire. **Results:** Seventy-two (67.3%) of the participants with bladder cancer were males. The mean age of participants with bladder cancer was  $59.24 \pm 16.28$  years. Most participants with bladder cancer worked as farmers (35.5%) or industrial workers (24.3%). Recent history of recurrent urinary tract infections was seen in 85 (79.4%) of the participants with bladder cancer and 32 (30.8%) of controls. Diabetes mellitus was more common among participants with bladder cancer. A significant number of participants with bladder cancer used tobacco and smoked compared to controls. **Conclusions:** This study highlights numerous potential biological and epidemiological factors that may act as a risk factors for bladder cancer. These factors could explain the gender differences observed in the incidence of bladder cancer. In addition, the study indicates the intense risk of tobacco products and smoking on the incidence of bladder cancer.

**Key words:** Alcohol, bladder cancer, epidemiology, gender, genetics, occupation, risk factors, tobacco smoking

### Introduction

The bladder is an organ that remains in constant contact with the environment and is, therefore, sensitive to the effects of environmental carcinogens

and inflammation.<sup>[1]</sup> Tobacco smoking and occupational hazards account for the two most frequent routes of environmental exposure. Tobacco smoke is full of aromatic amines. These amines, when hydroxylated, lead to DNA adduction and damage.<sup>[1]</sup>

Several risk factors have been identified for the occurrence of bladder cancer. These include genetic risk factors, hereditary factors, smoking and tobacco use, increased body mass index, occupational exposure to certain chemicals and dyes, medical conditions such as chronic cystitis and infectious diseases such as schistosomiasis. Indirect medical causes of bladder cancer are typically unintended side effects of treatment with certain drugs such as anti-diabetic drug pioglitazone, radiation, chemotherapy agents such as cyclophosphamide and environmental pollution through exposure to arsenic in drinking water.<sup>[1]</sup>

Bladder cancer is a global disease, with a worldwide incidence of 540,000 new cases and 188,000 deaths in 2015.<sup>[1]</sup> Internationally, the incidence of bladder cancer varies about 10-fold. The disease is reported most often in Europe and North America and least often in several areas of Asia.<sup>[2]</sup> Epidemiologic data clearly show that bladder cancer is much more common among men, Caucasians, and the elderly.<sup>[3]</sup> In most high-income countries, men have at least a 3 times greater risk than women.<sup>[4]</sup>

This study aimed to review the current state of knowledge regarding Bladder cancer risk factors, including factors related to occupation, diet, fluid intake, tobacco and smoking habits and concurrent medical conditions.

## Materials and Methods

The research was carried out at the Department of Urology of Doctor Prabhakar Kore Hospital and Medical Research Centre in Belagavi between September 2019 and May 2022. This prospective study was taken up after obtaining ethical clearance from the Institutional Review Board (KAHER/EC/20-21/001/05). All patients presenting to the uro-oncology outpatient department, the hospital admitted patients with signs or symptoms suggestive of bladder cancer and patients followed up for a history of treated bladder cancer were included in the study as cases. Age- and gender-matched patients presenting to the department of urology with symptoms and diagnosis of benign


prostatic hyperplasia, urinary stones, urinary tract infection and voiding dysfunction were prospectively included as controls.

All the study subjects and the controls completed a self-administered structured questionnaire (available on request from the corresponding author). Trained interviewers monitored the process. The questionnaire collected information on sociodemographic factors, lifestyle habits and diet 2 years before diagnosis, anthropometric measurements, problem-oriented medical history and family history of cancer. Two-specific sections investigated lifetime occupational exposure and exposure to chemicals known (or suspected) to be related to bladder cancer, including the use of hair dyes. Information on smoking included lifetime status (i.e., never, former, or current smoker), the daily number of cigarettes/beedis and grams of tobacco chewed, age at starting, duration of the habit and age at stopping for former smokers.

Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated using unconditional logistic regression models. ORs for status, intensity and duration of years were adjusted [Figure 1].

## Results

The study included 107 participants with imaging and histopathology confirmed bladder cancer and 104



**Figure 1:** Shows Odds ratios (ORs) and corresponding 95% confidence interval (CI) for smoking status, daily exposure, and duration of years.

**Table 1: Age and gender distribution of patients with bladder cancer**

Variables	Bladder cancer (%)			Controls n (%)			P-value
Males	72			68			0.001
Females	35			36			
Age (years)	Males	Females	Total	Males	Females	Total	0.001
<30	3	2	5 (4.7%)	4	2	6 (5.8%)	
31–60	32	17	49 (45.8%)	29	17	46 (44.2%)	
>70	37	16	53 (49.5%)	35	17	52 (50%)	

participants were age and gender-matched controls. Seventy-two (67.3%) participants with bladder cancer were males, and the remaining 35 (32.7%) were females. The cancer was significantly more common among males ( $P < 0.001$ ) when compared to females [Table 1]. The mean age of participants with bladder cancer was  $59.24 \pm 16.28$  years (males  $59.53 \pm 16.16$  and females  $58.66 \pm 16.75$ ). About 50% of the participants with bladder cancer were >70 years old. Most of the participants with bladder cancer worked as farmers (35.5%) or industrial workers (24.3%) [Table 2]. Most of the industry workers worked in chemical industry plants dealing with oils, rubber, paints and heavy metal chemicals.

Most participants in the bladder cancer group (89.7%) and controls (91.3%) were married. Recent history of recurrent urinary tract infections was noted in 85 (79.4%) of participants with bladder cancer and in 32 (30.8%) participants from the control group. Diabetes Mellitus was more common among participants with bladder cancer and a significantly high number of participants with bladder cancer gave a history of cancer (including bladder cancer) in the family. About 45% of the participants with bladder cancer gave an account of ingesting red meat [Table 3]. A significant number of participants with bladder cancer used tobacco and smoked compared to controls. Moreover, the number of participants continuing to use tobacco products, including cigarettes, even after diagnosis was significantly more [Table 4].

## Discussion

Bladder cancer is a common urological cancer and ranks as the seventh most common cancer

**Table 2: Occupation of the patients with bladder cancer**

Occupation	Bladder Cancer		Controls		P-value
	n	%	n	%	
Farming	38	35.5	32	30.8	0.83
Menial worker	8	7.5	13	12.5	0.75
Industry worker	26	24.3	15	14.4	<.05*
White-collared job	9	8.4	14	13.5	0.36
Business	13	12.1	5	4.8	<.05*
Homemaker	13	12.1	25	24.0	0.09
Total	107	100.00	104	100.00	

\* means statistically significant.

**Table 3: Association of various factors with bladder cancer**

Variable	Bladder cancer		Controls		Odds ratio
	n	%	n	%	
Married	96	89.7	95	91.3	0.826
Recent h/o recurrent UTI	85	79.4	72	69.2	1.7172
Family h/o cancer	11	10.3	2	1.9	5.843
Diabetes mellitus	31	29.0	12	11.5	3.127
Fluid intake (1Lt/day)	25	23.4	21	20.2	0.666
Non-vegetarian diet	86	84.1	75	72.1	2.0471
Pure vegetarian diet	21	15.9	29	27.8	1.458
Red meat consumption	41	45.6	25	29.1	2.265
Alcohol consumption	35	32.7	18	17.3	1.622

**Table 4: Use of tobacco products and smoking in patients with bladder cancer**

Variables	Bladder cancer		Controls		P-value
Tobacco users	60	56.1	40	38.4	<.01*
Smoking	51	47.7	32	30.8	<.01*

among men.<sup>[5]</sup> Bladder cancer is considerably more common in men than in women (the worldwide ratio is about 3.5:1), which has been regarded as a possible indication of an occupational origin.<sup>[6]</sup> Bladder cancer has been associated with occupational exposure to industrial carcinogens.<sup>[7]</sup> As early as the late 19<sup>th</sup> century, it has been reported that unusual incidences of bladder cancer exist in the industry.<sup>[8]</sup> Case and Hosker<sup>[9]</sup> reported an exceptionally high incidence of bladder cancer in the British rubber industry. Several other agents or occupations were later shown to be associated with an increased risk of bladder cancer. Exposure to polycyclic aromatic hydrocarbons in the aluminium, coal tar and coal gasification industries was also reported to be an increased risk.<sup>[7]</sup>

Painters were reported to be at high risk for developing bladder cancer.<sup>[10-13]</sup> Several epidemiological studies reported relative risks (RRs) between 1.2 and 1.5 among painters for bladder cancer.<sup>[7]</sup> Some studies have also reported on the increased risks of bladder cancer with increasing duration of exposure to paint components.<sup>[14,15]</sup> Several epidemiological studies have also reported an increased incidence of bladder cancer among lorry drivers, taxi drivers and bus drivers.<sup>[16-18]</sup> The RRs for bladder cancer in studies of these occupational groups varied from 1.3 to 2.2. Most studies found positive trends with the duration of exposure.<sup>[7]</sup> The most likely causal agent is the constituents of the diesel exhaust emissions. However, these associations have not always been confirmed and are still debated.

A bladder cancer diagnosis is 3-4 times more common in men than women. Numerous

explanations for this gender discrepancy in incidence have been offered, including disparate exposures to bladder cancer risk factors and the potential for sex steroid hormone regulation.<sup>[19]</sup> Women diagnosed with bladder cancer are more likely to have locally advanced tumours at the time of diagnosis.<sup>[20]</sup> Moreover, the female gender has been reported – albeit not uniformly – to be associated with higher risks of disease recurrence, progression and mortality after the treatment.<sup>[21-25]</sup> Dobruch *et al.*<sup>[19]</sup> reported that the gender difference in bladder cancer incidence was independent of differences in exposure risk, including smoking status. Potential molecular mechanisms included the disparate metabolism of carcinogens by hepatic enzymes between men and women, resulting in differential exposure of the urothelium to carcinogens. In addition, the sex steroid hormone pathway activity also played a role in bladder cancer development, demonstrating that both androgens and oestrogens have biological effects on bladder cancer *in vitro* and *in vivo*. Importantly, gender differences do exist in the timeliness and completeness of haematuria evaluation, with women experiencing a significantly more delay in urologic referral and less frequently undergoing guideline-concordant imaging. Correspondingly, women had more advanced tumours at the time of bladder cancer diagnosis. Interestingly, higher cancer-specific mortality was noted among women even after adjusting for tumour stage and treatment modality. Our study also shows that the incidence of bladder cancer is 2-3 times more common in men than in women.

Contemporary studies have underscored the importance of loss of heterozygosity on chromosomal arms 9p and 9q and inactivation of the p16 tumour suppressor gene as potential initiating events in the development of bladder cancer in adults.<sup>[26-28]</sup> The mutation of important cell cycle regulators, such as the p53 tumour suppressor gene on chromosomal arm 17p, has been tentatively associated with disease progression and a poor prognosis after surgical therapy for invasive tumours in adults.<sup>[29,30]</sup>

No association between alcohol and bladder cancer was found in a multicentric U.S. study of 2982 cases and a comparable number of controls.<sup>[31]</sup> On the contrary, a meta-analysis gave an overall RR for current drinkers versus non-drinkers of 1.3, a borderline significant.<sup>[32]</sup> Similarly, Pelucchi *et al.*<sup>[33]</sup> reported in a large case-control study on the issue for a population with frequent and heavy alcohol consumption revealed no consistent association between alcohol consumption and bladder cancer risk, the RRs being below unity also for six or more drinks of alcoholic beverages per day.

Tobacco smoking is a significant risk factor for bladder cancer,<sup>[34]</sup> responsible for about half the cases in both men and women.<sup>[34]</sup> The risk is generally threefold to fivefold higher in heavy smokers compared with never smokers, with a clear dose-response relationship for intensity.<sup>[35]</sup> A plateau in risk at approximately 20 cigarettes/day has also been reported in a pooled analysis of 11 case-control studies.<sup>[36]</sup> Furthermore, smoking duration has a high RR. The risk is fivefold higher in long-lasting smokers than in never smokers.<sup>[35,37,38]</sup> Although most studies focused on smoking intensity rather than duration,<sup>[35]</sup> the pooled analysis results suggested that smoking duration is the overriding factor in determining the risk of bladder cancer.<sup>[36]</sup>

Tobacco smoking has been consistently associated with bladder cancer invasiveness and grading.<sup>[39-42]</sup> These tumour characteristics strongly correlate with the papillary feature, which is crucial in the TNM classification to classify non-invasive bladder cancers into Ta or Tis. Polesei *et al.*<sup>[43]</sup> evaluated the impact of tobacco smoking on specific histological subtypes of transitional cell carcinoma of the bladder (TCC). Compared to never smokers, TCC risk was 3-fold higher in former smokers (95% CI 2.07-4.18) and more than 6-fold higher in current smokers (95% CI 4.54-9.85). TCC risk steadily increased with increasing intensity (OR for C25 cigarettes/day 8.75; 95% CI 3.40-22.55) and duration of smoking (OR for C50 years 5.46; 95% CI 2.60-11.49). No heterogeneity emerged

between papillary and non-papillary TCCs for smoking intensity and duration. Still, the risk for those who had smoked for C50 years was twice for non-papillary TCC (OR 10.88) compared with papillary one (OR 4.76). The risk for a 10-year increase in duration among current smokers grew across intensity strata ( $P = 0.046$ ). Conversely, the risk for a 5-cigarette/day increase in smoking intensity was relatively steady across duration strata ( $P = 0.18$ ). The authors concluded that the duration of smoking outweighed the intensity in determining TCC risk, with little differences across histological subtypes. Elimination of tobacco smoking could prevent about 65% of bladder TCC.

## Conclusion

In conclusion, according to the findings of this study, bladder cancer is associated with several risk factors, one of which is gender. The link between gender and bladder cancer is complicated and it is most likely influenced by various biological and epidemiological characteristics. Numerous factors, including the importance of the steroid hormone pathway, gender differences in chemical exposure, metabolic enzyme activity, disparities in dietary factors and India's consumption of alcohol and tobacco products, may explain these demographic trends. Tobacco use, cigarette smoking and industrial chemicals are the leading risk factors for bladder cancer.

## References

1. Kates M, Bivalacqua TJ. Tumours of the bladder. In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, editors. Campbell-Walsh-Wein Urology. 12<sup>th</sup> ed. Philadelphia, PA: Elsevier; 2020. p. 3073.
2. Janković S, Radosavljević V. Risk factors for bladder cancer. *Tumori* 2007;93:4-12.
3. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: Epidemiology, diagnosis, and management. *Cancer Pract* 2002;10:311-22.
4. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. *Int J Cancer* 1999;80:827-41.
5. Parkin DM, Vizcaino AP, Skinner ME, Ndhlovu A. Cancer patterns and risk factors in the African population of Southwestern Zimbabwe, 1963-77. *Cancer Epidemiol Biomarkers Prev* 1994;3:537-47.
6. Zeegers MP, Swaen GM, Kant I, Goldbohm RA, Van

- den Brandt PA. Occupational risk factors for male bladder cancer: Results from a population-based case cohort study in the Netherlands. *Occup Environ Med* 2001;58:590-6.
7. Schottenfeld D, Fraumeni JF. *Cancer Epidemiology and Prevention*. Oxford: Oxford University Press; 1996.
  8. Rehn L. Bladder unsteadiness in fuchsine workers. *Arch Klin Chir* 1895;50:588-600.
  9. Case RA, Hosker ME. Tumour of the urinary bladder as an occupational disease in the rubber industry in England and Wales. *Br J Prev Soc Med* 1954;8:39-50.
  10. Matanoski GM, Stockwell HG, Diamond EL, Haring-Sweeney M, Joffe RD, Mele LM, *et al*. A cohort mortality study of painters and allied tradesmen. *Scand J Work Environ Health* 1986;12:16-21.
  11. Bethwaite PB, Pearce N, Fraser J. Cancer risks in painters: Study based on the New Zealand cancer registry. *Br J Ind Med* 1990;47:742-6.
  12. Siemiatycki J, Dewar R, Nadon L, Gérin M. Occupational risk factors for bladder cancer: Results from a case-control study in Montreal, Quebec, Canada. *Am J Epidemiol* 1994;140:1061-80.
  13. Terstegge CW, Swaen GM, Slangen JJ, Van Vliet C. Mortality patterns among commercial painters in the Netherlands. *Int J Occup Environ Health* 1995;1:303-10.
  14. Jensen OM, Wahrendorf J, Knudsen JB, Sørensen BL. The Copenhagen case-referent study on bladder cancer. Risks among drivers, painters and certain other occupations. *Scand J Work Environ Health* 1987;13:129-34.
  15. Silverman DT, Levin LI, Hoover RN, Hartge P. Occupational risks of bladder cancer in the United States: I. White men. *J Natl Cancer Inst* 1989;81:1472-80.
  16. Baxter PJ, McDowall ME. Occupation and cancer in London: An investigation into nasal and bladder cancer using the cancer atlas. *Br J Ind Med* 1986;43:44-9.
  17. Claude JC, Frentzel-Beyme RR, Kunze E. Occupation and risk of cancer of the lower urinary tract among men. A case-control study. *Int J Cancer* 1988;41:371-9.
  18. Steenland K, Burnett C, Osorio AM. A case-control study of bladder cancer using city directories as a source of occupational data. *Am J Epidemiol* 1987;126:247-57.
  19. Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon A, Resnick MJ, *et al*. Gender and bladder cancer: A collaborative review of etiology, biology, and outcomes. *Eur Urol* 2015;69:300-10.
  20. Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. *Cancer* 2009;115:68-74.
  21. Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Roupêt M, *et al*. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: An inter-national multi-institutional study of more than 8000 patients. *Eur Urol* 2014;66:913-9.
  22. Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, *et al*. Gender-specific outcomes of bladder cancer patients: A stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. *Eur J Surg Oncol* 2015;41:368-77.
  23. Mitra AP, Skinner EC, Schuckman AK, Quinn DI, Dorff TB, Daneshmand S. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. *Urol Oncol* 2014;32:52.e1-9.
  24. Buteau A, Seideman CA, Svatek RS, Youssef RF, Chakrabarti G, Reed G, *et al*. What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. *Urol Oncol* 2014;32:128-34.
  25. Henning A, Wehrberger M, Madersbacher S, Pycha A, Martini T, Compoj E, *et al*. Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? *BJU Int* 2013;112:68-73.
  26. Rupert JM, Torino K, Sidransky D. Evidence for two bladder cancer suppressor gene loci on human chromosome 9. *Cancer Res* 1993;53:5093-5.
  27. Tsai YC, Nichols PW, Hiti AC. Allelic losses of chromosome 9, 11 and 17 in human bladder cancer. *Cancer Res* 1990;50:44-7.
  28. Kamb A, Gruis NA, Weaver-Feldman J. A cell cycle regulator potentially involved in genesis of many tumor types. *Science* 1994;284:436-40.
  29. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, *et al*. Identification of p53 mutations in bladder cancers and urine samples. *Science* 1991;252:706-9.
  30. Spruck CH 3<sup>rd</sup>, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, *et al*. Two molecular pathways to transitional cell carcinoma of the bladder. *Cancer Res* 1994;54:784-8.
  31. Thomas DB, Uhl CN, Hartge P. Bladder cancer and alcoholic beverage consumption. *Am J Epidemiol* 1983;118:720-7.
  32. Zeegers MP, Tan FE, Verhagen AP, Weijenberg MP, Van den Brandt PA. Elevated risk of cancer of the urinary tract for alcohol drinkers: A meta-analysis. *Cancer Causes Control* 1999;10:445-51.
  33. Pelucchi C, Negri E, Franceschi S, Talamini R, La Vecchia C. Alcohol drinking and bladder cancer. *J Clin Epidemiol* 2002;55:637-41.
  34. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. *JAMA* 2011;306:737-45.
  35. IARC Scientific Publications. IARC monographs on

- the evaluation of carcinogenic risks to humans. In: Tobacco Smoke and Involuntary Smoking. Vol. 83. Lyon: IARC Scientific Publications; 2004.
36. Brennan P, Bogilot O, Cordier S, Greiser E, Schill W, Vineis P, *et al.* Cigarette smoking and bladder cancer in men: A pooled analysis of 11 case-control studies. *Int J Cancer* 2000;86:289-94.
  37. Samanic C, Kogevinas M, Dosemici M, Malats N, Real FX, Garcia-Closas M, *et al.* Smoking and bladder cancer in Spain: Effects of tobacco type, timing, environmental tobacco smoke, and gender. *Cancer Epidemiol Biomarkers Prev* 2006;15:1348-54.
  38. Baris D, Karagas MR, Verrill C, Johnson A, Andrew AS, Marsit CJ, *et al.* A case-control study of smoking and bladder cancer risk: Emergent patterns over time. *J Natl Cancer Inst* 2009;101:1553-61.
  39. Hinotsu S, Akaza H, Miki T, Fujimoto H, Shinohara N, Kikuchi E, *et al.* Bladder cancer develops 6 years earlier in current smokers: Analysis of bladder cancer registry data by the cancer registration committee of the Japanese urological association. *Int J Urol* 2009;16:64-9.
  40. Pietzak EJ, Malkowicz SB. Does quantification of smoking history correlate with initial bladder tumor grade and stage? *Curr Urol Rep* 2014;15:416.
  41. Jiang X, Castelao JE, Yuan JM, Stern MC, Conti DV, Cortessis VK, *et al.* Cigarette smoking and subtype of bladder cancer. *Int J Cancer* 2012;130:896-901.
  42. Sturgeon SR, Hartge P, Silverman DT, Kantor AF, Linehan WM, Lynch C, *et al.* Association between bladder cancer risk factors and tumor stage and grade at diagnosis. *Epidemiology* 1994;5:218-25.
  43. Polesei J, Bosetti C, Di Maso M, Montella M, Libra M, Garboglio A, *et al.* Duration and intensity of tobacco smoking and the risk of papillary and non-papillary transitional cell carcinoma of the bladder. *Cancer Causes Control* 2014;25:1151-8.

### Author Contributions

Conceived and designed the analysis: SR, RBN and SCG, Collected the data: SR and SRB, Contributed data or analysis tools: SR, SRB and SCG, Performed the analysis: SR and SRB and Wrote the paper: SR, RBN and SCG.